Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | MAT2A | P31153 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30538010 | 1.00 | TMEM97 (0.52) | TMEM97SIGMAR1CMA1MAT2AKDM4E | |
| SCHEMBL4614580 | 0.85 | SIGMAR1 (0.53) | TMEM97SIGMAR1MAPTTP53THRB | |
| SCHEMBL9886026 | 0.79 | CYP2A6 (0.44) | SIGMAR1GPR55MAPTL3MBTL1RAB9A | |
| SCHEMBL29704509 | 0.78 | SIGMAR1 (0.47) | SIGMAR1GPR55MAPTLMNARAB9A | |
| SCHEMBL14726178 | 0.78 | BRPF1 (0.43) | SIGMAR1KDM4EGPR55MAPTTDP1 | |
| SCHEMBL14112013 | 0.78 | GPR55 (0.38) | TMEM97SIGMAR1GPR55MAPTTP53 | |
| SCHEMBL19644301 | 0.78 | SIGMAR1 (0.47) | SIGMAR1GPR55MAPTLMNARAB9A | |
| SCHEMBL19657871 | 0.78 | GPR55 (0.38) | TMEM97SIGMAR1GPR55MAPTTP53 | |
| SCHEMBL14086888 | 0.77 | TMEM97 (0.46) | TMEM97SIGMAR1CMA1KDM4EMAPT | |
| SCHEMBL10980672 | 0.76 | TMEM97 (0.45) | TMEM97SIGMAR1CMA1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4548972-A2 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2025-05-07 | — | — | EP | disclosed |
| EP-3744714-B1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2025-01-15 | — | — | EP | disclosed |
| US-20240336582-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2024-10-10 | — | — | US | disclosed |
| US-12054465-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2024-08-06 | — | — | US | disclosed |
| US-20240132455-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-25 | — | — | US | disclosed |
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-11-14 | — | — | US | disclosed |
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230250071-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2023-08-10 | — | — | US | disclosed |
| CN-110483492-B | Dipeptidyl peptidase I inhibitors | 阿斯利康(瑞典)有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-9522894-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2016-12-20 | — | — | US | disclosed |
| EP-3097086-A1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | Astrazeneca AB (SE) | 2016-11-30 | — | — | EP | disclosed |
| US-20150210655-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2015-07-30 | — | — | US | disclosed |
| WO-2015110826-A1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2015-07-30 | — | — | WO | disclosed |
| US-20090130165-A1 | MIF Inhibitors | CORTICAL PTY LTD | 2009-05-21 | — | — | US | disclosed |
| EP-1968576-A1 | MIF INHIBITORS | Cortical Pty Ltd (AU) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007070961-A1 | MIF INHIBITORS | CORTICAL PTY LTD (AU) | 2007-06-28 | — | — | WO | disclosed |
| EP-0137083-B1 | 1,5-BENZOTHIAZEPINE DERIVATIVES AND PRODUCTION THEREOF | HAMARI YAKUHIN KOGYO KABUSHIKI KAISHA also known as HAMARI CHEMICALS, LTD. (JP) | 1987-06-24 | — | — | EP | disclosed |
| EP-0137083-A1 | 1,5-Benzothiazepine derivatives and production thereof | HAMARI YAKUHIN KOGYO KABUSHIKI KAISHA also known as HAMARI CHEMICALS, LTD. (JP) | 1985-04-17 | — | — | EP | disclosed |
| US-4490292-A | 1,5-Benzothiazepine derivatives and production thereof | HAMARI CHEMICALS, LTD. (JP) | 1984-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132455-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | TMEM97 3758/4885SIGMAR1 2192/4885CMA1 20/4885 |
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | TMEM97 3762/4885SIGMAR1 2219/4885CMA1 20/4885 |
| US-20230250071-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | TMEM97 3758/4885SIGMAR1 2192/4885CMA1 20/4885 |
| US-12054465-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | TMEM97 3758/4885SIGMAR1 2192/4885CMA1 20/4885 |
| US-20240336582-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | TMEM97 3758/4885SIGMAR1 2192/4885CMA1 20/4885 |
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | TMEM97 3779/4885SIGMAR1 2093/4885CMA1 20/4885 |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | TMEM97 3762/4885SIGMAR1 2219/4885CMA1 20/4885 |
| US-20090130165-A1 | MIF Inhibitors | MIF, MMP12, IL4 | TMEM97 2212/4885SIGMAR1 3403/4885CMA1 92/4885 |
| US-20150210655-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | TMEM97 3762/4885SIGMAR1 2219/4885CMA1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.